Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry

Main Article Content

Bruce Strober
Michael Singleton
Alvin H. Li
Rhiannon Dodge
Wanyi Chen
Kayla Callahan
Megan Phillips
Prajakta Masurkar
Heather Herr
Braulio Gomez
Robert Low
Jeffrey Stark

Keywords

Psoriasis, Patient-Report Outcomes, Registry, Bimekizumab, real-world evidence, Treatment persistence

References

1. Reich K et al. N Engl J Med. 2021;385(2):142–152;

2.Warren RB et al. N Engl J Med. 2021;385(2):130–141;

3. Reich K et al. Lancet. 2021;397(10273):487–498;

4. Gordon KB et al. Lancet. 2021;397(10273):475–486;

5. Langley RG et al. American Association of Dermatology 2025. Presentation #63312.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/6744kd41

Article Details

How to Cite
1.
Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry. J of Skin. 2025;9(6):s632. doi:10.25251/6744kd41
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>